☆ 4.6 Meeting Abstract

LONG-TERM COST-CONSEQUENCE ANALYSIS OF EXENATIDE ONCE WEEKLY VERSUS SITAGLIPTIN OR PIOGLITAZONE IN TYPE 2 DIABETES PATIENTS IN THE UNITED STATES

VALUE IN HEALTH (2010)

Journal

VALUE IN HEALTH

Volume 13, Issue 7, Pages A290-A290

Publisher

WILEY-BLACKWELL PUBLISHING, INC

DOI: 10.1016/S1098-3015(11)72094-0

Keywords

-

Categories

Economics Health Care Sciences & Services Health Policy & Services

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.